The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM
Year: 2021
Type: article
Study design: Observational Study
Abstract: Aims To describe glycaemic control and diabetes management in adults with type 1 diabetes (T1DM), in a real‐life global setting. Materials and Methods Study of Adults' GlycEmia (SAGE) was a multinational, multicentre, single visit, noninterventional, cross‐sectional study in adult patients with T1DM. Data were collected at a single visit, analysed according to predefined age groups (26–44, 45–64 and ≥65 years) and reported across different regions. The primary endpoint was the proportion of participants achieving HbA 1c less than 7.0 % in each age group. Secondary endpoints included incidence of hypoglycaemia, severe hypoglycaemia and severe hyperglycaemia leading to diabetic ketoacidosis (DKA) and therapeutic management of T1DM. Results Of 3903 included participants, 3858 (98.8%) were eligible for the study. Overall, 24.3% (95% confidence interval [CI]: 22.9–25.6) of participants achieved the glycaemic target of HbA 1c less than 7.0 %, with more participants achieving this target in the 26–44 years group (27.6% [95% CI: 25.5–29.8]). Target achievement was highest in Eastern and Western Europe, and lowest in the Middle East. The incidence of hypoglycaemia and of severe hyperglycaemia leading to DKA tended to decrease with age, and varied across regions. Age and regional differences were observed in therapeutic management, including types of device/insulin usage, frequency of insulin dose adjustment and technology usage. Conclusions Glycaemic control remains poor in adults with T1DM globally. Several areas of treatment may be optimised to improve outcomes, including supporting patient self‐management of insulin therapy, increasing use of technologies such as CGM, and greater provision of healthcare support.
DOI: 10.1002/dmrr.3430
Institutions: Centre National de la Recherche Scientifique, Inserm, Université de Montpellier, Centre Hospitalier Universitaire de Montpellier, Institut de Génomique Fonctionnelle, Kindai University, Università Campus Bio-Medico, Queen Mary University of London, Sanofi (France), University of Southern California, University of Rijeka, Klinički Bolnički Centar Rijeka, Jothydev's Diabetes and Research Center, University of Freiburg, University Hospitals of Derby and Burton NHS Foundation Trust
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,100
Funders: Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Sanofi, Intarcia Therapeutics, Insulet Corporation, Dexcom, Tandem Diabetes Care, Novo Nordisk, Astellas Pharma, Otsuka Pharmaceutical, Servier, Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical, Ipsen, Abbott Diabetes Care, Eli Lilly Japan, Japan Society for the Promotion of Science, National Institute of Diabetes and Digestive and Kidney Diseases, Daiichi Sankyo Europe
OpenAlex ID: W3116343197
